Retrospective Analysis of Glecaprevir/Pibrentasvir Safety and Concomitant Medications Through Integrated Real-World Data
Status: Recruiting
Location: See all (2) locations...
Study Type: Observational
SUMMARY
The objective of this study is to assess the safety, tolerability and effectiveness of 8-week Glecaprevir/Pibrentasvir (G/P) in participants taking either prescribed or illicit drugs.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Prescribed 8 weeks of Glecaprevir/Pibrentasvir (G/P).
• Treatment-naïve (for the current infection, participants that may have had prior infections which were resolved with treatment are considered naive for current infection as long as they have not received any treatment for the current infection.)
• Is concomitantly on one or more prescription medications or illicit drugs.
Locations
Other Locations
Canada
St. Clair Medical Clinic /ID# 275334
RECRUITING
Toronto
Vancouver Infectious Diseases Centre /ID# 275313
RECRUITING
Vancouver
Contact Information
Primary
Dimitri Semizarov
dimitri.semizarov@abbvie.com
+1 847-935-8741
Time Frame
Start Date: 2026-02-27
Estimated Completion Date: 2026-06
Participants
Target number of participants: 2000
Treatments
Glecaprevir/Pibrentasvir
Data from participants prescribed Glecaprevir/pibrentasvir will be collected.
Related Therapeutic Areas
Sponsors
Leads: AbbVie